CERT

Rating neutralAI Memo

Certara

As of 2026-05-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Veristat divestiture close could reset guidance and simplify the story • 2026-06-30

Expected move: +0%

Biggest risk

The negative case is that 2026 guidance started weak at 0-4% revenue growth with 30-32% adjusted EBITDA margin, software bookings fell 6% in 4Q25 on external factors and execution challenges, and the pending sale makes near-term comparability and guidance quality less clear until closing.

Invalidation

Break below $5 or thesis failure.

What would change my mind?

The positive case is that Certara is simplifying around higher-value MIDD and Clinical Intelligence, had 4Q25 total bookings up to $155.2 million with service bookings up 17% year over year, and can redeploy divestiture proceeds into product innovation and execution while exiting a lower-focus services asset.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-06

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 2026 results on May 11 test whether bookings convert into cleaner growth
MIDD and Clinical Intelligence focus needs to show durable software-led adoption
The positive case is that Certara is simplifying around higher-value MIDD and Clinical Intelligence, had 4Q25 total bookings up to $155.2 million with service bookings up 17% year over year, and can redeploy divestiture proceeds into product innovation and execution while exiting a lower-focus services asset.

BearKey bullets

2026 revenue guidance of 0-4% and adjusted EBITDA margin guidance of 30-32% leave limited room for execution misses.
4Q25 software bookings declined 6% year over year, with management citing external factors and execution challenges.
Biopharma R&D spending, FDA and other government-agency policy changes, and customer renewal timing remain important external demand variables for Certara's software and services base.

WatchKey bullets

Veristat divestiture close could reset guidance and simplify the story

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $7 (p=50%)

Bull/Bear spread: +35% / -31%

Vs latest close: Bull +35% · Base +0% · Bear -31%

Scenario probabilities

Bull Target: $9 (p=25%)Base Target: $7 (p=50%)Bear Target: $5 (p=25%)

Commentary

Primary-source tone is mixed rather than strongly bullish: late-February results showed modest revenue growth and positive bookings but weak GAAP earnings and a low-growth 2026 guide, while the April 22 divestiture added a credible strategic simplification angle. News flow is active enough to keep headline buzz medium, but no reliable social-coverage packet was provided, market-reaction evidence is thin, and the deterministic prior remains near neutral with only moderate evidence quality, so this still reads as a monitoring setup rather than a high-conviction rerating call.

As of 2026-05-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 2026 results on May 11 test whether bookings convert into cleaner growth
MIDD and Clinical Intelligence focus needs to show durable software-led adoption

Scenarios

Bull Target (Scenario probability)

$9 / p=25% prob

Base Target (Scenario probability)

$7 / p=50% prob

Bear Target (Scenario probability)

$5 / p=25% prob

Price $7 as of 2026-07-13

Nearest Scenario: Base (∆ 0%)

Targets vs latest close: Bull +35% · Base +0% · Bear -31%

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-30
Veristat divestiture close could reset guidance and simplify the story
On April 21, 2026 Certara agreed to sell its regulatory and medical writing business to Veristat for $100 million in cash plus up to $35 million of contingent consideration, with close expected in Q2 2026; management said updated 2026 guidance will be provided upon closing [#8-K-2026-04-22]. The asset generated $50 million of 2025 revenue and $17 million of adjusted EBITDA excluding unallocated overhead [#8-K-2026-04-22].
Prob 75.00% • Move 10.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Q1 2026 results on May 11 test whether bookings convert into cleaner growth
2026-05-11
Certara said it will report first-quarter 2026 results on May 11, 2026 [#IR-2026-04-09]. The key near-term check is whether strong 4Q25 service bookings growth and a sharper MIDD software focus begin to offset the weak 2026 starting guide and prior software execution issues [#PR-2026-02-26].
Prob 70% • Move 8% • Priced-in 55%

Long-term Catalysts

Months to a year

MIDD and Clinical Intelligence focus needs to show durable software-led adoption
2026-12-31
Management framed the divestiture as a sharper focus on Model-Informed Drug Development and Clinical Intelligence, while Certara's March 3 release highlighted a Simcyp use case replacing ten human trials for asciminib, reinforcing the regulatory and customer-adoption case for biosimulation-led workflows [#8-K-2026-04-22] [#PR-2026-03-03]. The longer-term upside depends on translating that adoption narrative into faster software growth and steadier margins.
Prob 45% • Move 15% • Priced-in 35%

Risks

2026 revenue guidance of 0-4% and adjusted EBITDA margin guidance of 30-32% leave limited room for execution misses.
4Q25 software bookings declined 6% year over year, with management citing external factors and execution challenges.
Biopharma R&D spending, FDA and other government-agency policy changes, and customer renewal timing remain important external demand variables for Certara's software and services base.
The Veristat transaction has customary closing conditions; delay, repricing, or a failed close would likely pressure confidence and keep guidance muddy.

Peers

Symbol	Summary
SLP	Simulations Plus is the closest public biosimulation software peer; it is more directly exposed to modeling-and-simulation software demand, making it the cleanest read-through for Certara's MIDD-focused software thesis.
IQV	IQVIA is a broader life-sciences technology and clinical-services peer; it is less pure-play than Certara but relevant for benchmarking clinical intelligence, software-enabled services, and biopharma spending sensitivity.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-06

AI Stock Memo: CERT - Certara - RankAlpha